The Policy and Planning Service (PPS) respectfully informs the pharmaceutical stakeholders of the posting of the 5th Draft of the APRF Agreement for inputs/comments. Kindly see the attached electronic copy of the draft agreement in the FDA Website for your reference and information.
All comments shall be sent via email at [email protected] following the subject format: COMMENTS_DRAFT APRF AGREEMENT. We hope to receive the inputs on or before 31 March 2023 for consolidation and subsequent submission to the ASEAN Secretariat.
For your information and guidance.